Lexicon Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference
Lexicon Pharmaceuticals announced that Jeffrey L. Wade, President and CFO, will present at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 8:45 a.m. ET. The event will be available via webcast on Lexicon's website, with an archived version accessible for two weeks post-event.
Lexicon focuses on pioneering medicines through its Genome5000™ program, identifying therapeutic targets across various diseases. The company has one medicine on the market and a pipeline in clinical and preclinical stages, including treatments for heart failure, neuropathic pain, and diabetes.
- None.
- None.
THE WOODLANDS, Texas, April 07, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, Lexicon’s president and chief financial officer, will present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 8:45 a.m. ET.
A webcast of the event will be available in the “Events” section of the Lexicon website at www.lexpharma.com. An archived version of the webcast will be available on the website for two weeks.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of sotagliflozin, LX9211 and its other potential drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin, LX9211 and its other potential drug candidates on its anticipated timelines, successfully commercialize any products for which it obtains regulatory approval, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Inquiries:
Chas Schultz
Executive Director, Corporate Communications and Investor Relations
(281) 863-3421
cschultz@lexpharma.com
FAQ
When will Lexicon Pharmaceuticals present at the Needham Virtual Healthcare Conference?
How can I access the webcast of the Lexicon Pharmaceuticals presentation?
What is the focus of Lexicon Pharmaceuticals' Genome5000 program?
What diseases is Lexicon Pharmaceuticals developing treatments for?
What is the ticker symbol for Lexicon Pharmaceuticals?
